Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 27:8:146.
doi: 10.3389/fendo.2017.00146. eCollection 2017.

Thyroid Autoimmunity and Lichen

Affiliations
Review

Thyroid Autoimmunity and Lichen

Fabrizio Guarneri et al. Front Endocrinol (Lausanne). .

Abstract

Lichen planus (LP) and lichen sclerosus (LS) are cutaneous-mucous diseases with uncertain epidemiology. Current data, which are likely to be underestimated, suggest a prevalence in the general population of 0.1-4% for cutaneous LP, 1.27-2.0% for oral LP, and 0.1-3.3% for LS. While etiology of lichen is still unknown, clinical and histological evidence show an (auto)immune pathogenesis. Association of lichen with autoimmune thyroid disease (AITD) has been investigated in few studies. This association appears better defined in the case of LS, while is more controversial for LP. In both situations, the frequency of the association is higher in females. We review the available literature on the correlation between the different types of lichen and AITD, and the literature on the genetic risk factors which are shared by both conditions. Such data suggest that a common pathogenic mechanism could be the cause for co-occurrence of lichen and AITD, at least in some patients. Additionally, analyzing literature data and in continuity with our previous work on other autoimmune diseases, we suggest that molecular mimicry could trigger both diseases, and thus explain their co-occurrence.

Keywords: autoimmune thyroid disease; cutaneous lichen planus; human leukocyte antigen; infections; lichen sclerosus; molecular mimicry; mucous lichen planus; oral lichen planus.

PubMed Disclaimer

References

    1. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. Berlin: Springer Verlag; (2000).
    1. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med (2012) 366:723–32.10.1056/NEJMcp1103641 - DOI - PubMed
    1. Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev (2011) 7:CD001168.10.1002/14651858.CD001168.pub2 - DOI - PubMed
    1. van Cranenburgh OD, Nijland SB, Lindeboom R, de Korte J, de Rie MA, Ter Stege JA, et al. Patients with lichen sclerosus experience moderate satisfaction with treatment and impairment of quality of life: results of a cross-sectional study. Br J Dermatol (2017) 176:1508–15.10.1111/bjd.15125 - DOI - PubMed
    1. Goolamali SK, Barnes EW, Irvine WJ, Shuster S. Organ-specific antibodies in patients with lichen sclerosus. Br Med J (1974) 4:78–9.10.1136/bmj.4.5936.78 - DOI - PMC - PubMed

LinkOut - more resources